Professional
Added to YB: 2025-07-11
Pitch date: 2025-06-30
MEDCL.PA [bullish]
MedinCell S.A.
+56.46%
current return
Author Info
Norbury Capital manages a concentrated Europe-focused investment fund, focused on entrepreneurial small and midcap companies. Sign up for the newsletter.
Company Info
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Market Cap
EUR 991.5M
Pitch Price
EUR 16.72
Price Target
N/A
Dividend
N/A
EV/EBITDA
-105.20
P/E
-48.15
EV/Sales
35.59
Sector
Pharmaceuticals
Category
growth
Norbury Capital Portfolio Holding: MedinCell S.A.
MEDCL.PA: French biotech with BEPO technology for long-acting injectables (LAI). Partners with pharma cos, earning milestones + high single-digit royalties. Uzedy (schizophrenia) w/Teva could earn $100M royalties; Olanzapine LAI approval expected H2 2024 with $200M potential. AbbVie pipeline of 6 more drugs. Breakeven soon, €150M+ net income potential.
Read full article (2 min)